SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
NewTimeSpace News: On 13 July 2026, SSY GROUP (02005.HK) released a voluntary announcement. Baloxavir Marboxil of the Group has obtained registration approval from the National Medical Products Administration (NMPA) of China as an active pharmaceutical ingredient to be applied in marketed pharmaceutical formulations. The Group becomes the third domestic enterprise receiving such approval. Baloxavir Marboxil is mainly used for the treatment of Influenza A and Influenza B virus infections.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
